Generate BiomedicinesNew York, New York, United States
Disclosure(s): Generate Biomedicines: employee
89 - First-in-human study of a novel half-life extended monoclonal antibody (GB-0669) against SARS-CoV2 and related sarbecoviruses
Thursday, October 17, 202410:54 AM – 11:06 AM US PT